Document is current
Any future updates will be listed below
-
Authors
Dimitriou, Florentia
Wu, Xiaogang
Nagarajan, Priyadharsini
Glitza, Isabella C.
Zhao, Li
Ning, Jing
Patel, Sapna P.
Wargo, Jennifer A.
Futreal, Andrew
Woodman, Scott
McQuade, Jennifer L.
Esmaeli, Bita
- License Information
-
More Information
Article History
Received: 19 February 2025
Accepted: 30 September 2025
First Online: 19 November 2025
Competing interests
: ICG reports research support from BMS, MERCK, and Pfizer, and advisory board relationships with Leal Pharmaceutics, BMS, MERCK, Pfizer, and Novartis. S.P.P. reports institutional clinical trial support from Foghorn Therapeutics, Ideaya, InxMed, Lyvgen Biopharma, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Bio, and TriSalus Life Sciences, and advisory board, steering committee, data safety monitoring board, consulting relationships with Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Ideaya, Immatics, IO Biotech, MSD, Novartis, Obsidian, OncoSec, Pfizer, Replimune, Scancell, TriSalus Life Sciences, Veda Trials. J.L.M. served as a consultant for Roche, BMS, and Merck unrelated to this work. All other authors have declared no conflicts of interest.
